References
- Global Initiative for Asthma. Global strategy for asthma management and prevention NHLBI/WHO Workshop Report issued 1995 and revised 2002. Adapted from National Heart, Lung and Blood Institute, National Institutes of Health; Publication number 02–3659. 2002. The 2002 report is available on www.ginasthma.com
- National Asthma Education and Prevention Program. VanGraafeiland B. Nurse Pract 2002;27(Suppl 1):7–12
- Warner JO, Naspitz CK. Third international pediatric consensus statement on the management of childhood asthma: International Pediatric Asthma Consensus Group. Pediatr Pulmonol 1998;25:1–17
- Bisgaard H. Long-acting b-agonists in management of childhood asthma: a critical review of the literature. Pediatr Pulmonol 2000;29:221–34
- Wallin A, Sandstrom T, Rosenhall L, Melander B. Time course and duration of bronchodilation with formoterol dry powder in patients with stable asthma. Thorax 1993;48(6):611–14
- Van Noord JA, Smeets JJ, Raaijmakers JA, Bommer AM, Maesen FP. Salmeterol versus formoterol in patients with moderately severe asthma; onset and duration of action. Eur Respir J 1996;9:1684–8
- Akpinarli A, Tuncer A, Saraclar Y, Sekerel BE, Kalayci O. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomised controlled trial. Arch Dis Child 1999;81:45–8
- Heuck C, Heickendorff L, Wolthers OD. A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch Dis Child 2000;83(4):334–9
- Price JF. Choices of therapy for exercise-induced asthma in children. Allergy 2001;56(S66):12–17
- Grönneröd TA, von Berg A, Schwabe G, Soliman S. Formoterol via Turbohalerâ gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respir Med 2000;94: 661–7
- Henriksen JM, Agertoft L, Pedersen S. Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children. J Allergy Clin Immunol 1992;89:1176–82
- de Blic J, Kuusela LA. Formoterol dry powder capsules for inhalation in children with asthma treated over one year. Eur Resp J 1995;8(Suppl 19):145 (Abstr)
- Verberne AAPH, de Jongste JC. Long-acting b-agonists in childhood asthma: don’t change a winning team (yet). Pediatr Pulmonol 2000;29:169–71
- Bensch G, Berger WE, Blokhin BM, Socolovsky AL, Thomson MH, Till MD, Castellsague MPH, Della Cioppa G. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Asthma Allergy Immunol 2002;89:180–90
- Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15(2):75–88
- Meakin BJ, Dimond PD. Bricanyl Turbohaler, Serevent Accuhaler & Foradil Aerolizer: comparative drug delivery. Thorax 1996;51(Suppl 3):A73 (Abstr)
- Nielsen KG, Skov M, Klug B, Ifversen H, Bisgaard H. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer™. Eur Resp J 1997;10:2105–9
- Mehra S, Bronsky EA, Pfister P. The Aerolizer™ dry powder inhaler allows successful administration of formoterol to pediatric and adult patients with varying degrees of asthma. Chest 2002;122(Suppl):83S (Abstr)